Discover REAfinity™ Recombinant Antibodies with augmented reality

- High lot-to-lot consistency
- No more background signal
- One universal isotype control

miltenyibiotec.com/augmentedreality
What are REAfinity™ Antibodies?

REAfinity™ Antibodies are recombinantly generated antibodies that provide superior lot-to-lot consistency and purity, as compared to mouse or rat monoclonal antibodies. They have been engineered to lack any background binding. Additionally, they all have the same human IgG1 isotype, eliminating any need to include multiple isotype controls during flow analysis.

Flow cytometry is in their genes

REAfinity Antibodies are generated by cloning the antigen-binding regions from traditional mouse or rat monoclonal antibodies derived from hybridomas with the human IgG1 Fc region. The two genetic regions are fused at the DNA level to create one antibody-defining genetic element (fig. 1). To eliminate background signal during analysis, the human IgG1 Fc region used for generating this fusion gene is mutated, abolishing any binding of the recombinantly engineered antibodies to FcγRs. To guarantee maximum purity and lot-to-lot consistency, a biologically and chemically defined in vitro expression system is used to produce REAfinity Antibodies.

Explore our REAfinity Antibodies with the Miltenyi Biotec augmented reality app

1. Download Miltenyi Biotec’s augmented reality app from the Apple® App Store.

2. Start the app.

3. Click on “AR view”.

4. Scan the front page of the flyer.

5. Bring the REAfinity Antibody 3D model to live and explore its unique features.

To find out more about REAfinity Antibodies, visit: www.miltenyibiotec.com/reafinity